Trial reportMolecular imaging and biology2010
A novel fluorescent imaging agent for diffuse optical tomography of the breast: first clinical experience in patients.
Trial report in Molecular imaging and biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 74 citations in OpenAlex.
- Oral Administration of a Bivalent Carbonic Anhydrase IX Near-Infrared Imaging Agent Detects Hypoxic Tumors in a Mouse Model.ACS sensors · 2026Article
- Fluorescence Imaging of Cancer.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- Fluorescent Probes for Imaging in Humans: Where Are We Now?ACS nano · 2023Review
- Indocyanine Green-Camptothecin Co-Loaded Perfluorocarbon Double-Layer Nanocomposite: A Versatile Nanotheranostics for Photochemotherapy and FDOT Diagnosis of Breast Cancer.Pharmaceutics · 2021Article
- Oral Administration and Detection of a Near-Infrared Molecular Imaging Agent in an Orthotopic Mouse Model for Breast Cancer Screening.Molecular pharmaceutics · 2018Article
- The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer.Oncotarget · 2017Article
- Hypoxia-Targeting Fluorescent Nanobodies for Optical Molecular Imaging of Pre-Invasive Breast Cancer.Molecular imaging and biology · 2016Article
- US-localized diffuse optical tomography in breast cancer: comparison with pharmacokinetic parameters of DCE-MRI and with pathologic biomarkers.BMC cancer · 2016Article
- Noninvasive Surface Imaging of Breast Cancer in Humans using a Hand-held Optical Imager.Biomedical physics & engineering express · 2015Article
- Intraoperative imaging-guided cancer surgery: from current fluorescence molecular imaging methods to future multi-modality imaging technology.Theranostics · 2014Review
- Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma.Molecular imaging and biology · 2013Article
- Dynamic dual-tracer MRI-guided fluorescence tomography to quantify receptor density in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Three-dimensional fluorescence tomography of human breast tissues in vivo using a hand-held optical imager.Physics in medicine and biology · 2013Article
- Combined hemoglobin and fluorescence diffuse optical tomography for breast tumor diagnosis: a pilot study on time-domain methodology.Biomedical optics express · 2013Article
- Parametric estimation of 3D tubular structures for diffuse optical tomography.Biomedical optics express · 2013Article
- Article
- Fluorescent nanoprobes dedicated to in vivo imaging: from preclinical validations to clinical translation.Molecules (Basel, Switzerland) · 2012Review
- Optical imaging with her2-targeted affibody molecules can monitor hsp90 treatment response in a breast cancer xenograft mouse model.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Article
- Near-infrared optical mammography for breast cancer detection with intrinsic contrast.Annals of biomedical engineering · 2012Review
- Split operator method for fluorescence diffuse optical tomography using anisotropic diffusion regularisation with prior anatomical information.Biomedical optics express · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis is the first clinical evaluation of a novel fluorescent imaging agent (Omocianine) for breast cancer detection with diffuse optical tomography (DOT). PROCEDURES: Eleven women suspected of breast cancer were imaged with DOT at multiple time points (up to 24 h) after receiving an intravenous injection of Omocianine (doses 0.01 to 0.1 mg/kg bodyweight). Breast MRI was obtained for comparison.
resultsHistopathology showed invasive cancer in ten patients and fibroadenoma in one patient. With the lowest dose of Omocianine, two of three lesions were detected; with the second dose, three of three lesions were detected; with the two highest doses, none of five lesions were detected. Lesion location on DOT showed excellent agreement with MRI. Optimal lesion-to-background signals were obtained after 8 h. No adverse events occurred.
conclusionsLowest doses of Omocianine performed best in lesion detection; DOT using a low-dose fluorescent agent is feasible and safe for breast cancer visualization in patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.